Journal
KIDNEY & BLOOD PRESSURE RESEARCH
Volume 43, Issue 5, Pages 1677-1687Publisher
KARGER
DOI: 10.1159/000494745
Keywords
MyD88; Epithelial-mesenchymal transition; Renal interstitial fibrosis; NF-kappa B; Transforming growth factor beta 1
Funding
- National Natural Science Foundation of China [81802895, 81672946, 81471588]
- Health and Family Planning Commission of Wuhan Municipality [WX17Q16]
Ask authors/readers for more resources
Background/Aims: The TLR/MyD88/NE-KB signaling pathway has been successfully used to treat renal interstitial fibrosis (RIF). However, the exact therapeutic mechanism is still unknown. Here, we assessed the therapeutic efficacy of TJ-M2010-2, a small molecular compound that inhibits MyD88 homodimerization, in RIF induced by ischemia reperfusion injury (IRO. Methods: In vivo, RIF was induced in mice by IRI, and the mice were prophylactically treated with TJ-M2010-2. In vitro, HK-2 cells were incubated with TGF-p1 to induce EMT, and the cells were pretreated with TJ-M2010-2. Results: We found that, compared with the IRI group, the TJ-M2010-2 group showed marked attenuation of RIF and renal function injury; decreased expression of TGE-beta 1, a-SMA, vimentin. MMP2 and MMP9; and increased E-cadherin expression. Furthermore, TGF-beta 1-induced EMT was blocked by TJ-M2010'2 in HK-2 cells, as evidenced by blocked morphologic transformation, restored E-cadherin expression and inhibited a-SMA expression. In addition, compared to the TGF-p1 group, the TJ-M2010-2 group showed profound inhibition of the expression of TRAF6, p65 and Snail and upregulation of the expression of IKBa. Conclusion: This MyD88 inhibitor may be a potential therapeutic agent to ameliorate RIF. (C) 2018 The Auther(s) Published by S. Karger AG, Basel
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available